- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03240809
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
August 9, 2023 updated by: Bausch Health Americas, Inc.
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis
Study Type
Interventional
Enrollment (Estimated)
16
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sandra Narain
- Phone Number: 908.242.8287
- Email: sandra.narain@bauschhealth.com
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Recruiting
- Bausch Site 003
-
-
Florida
-
Miami, Florida, United States, 33155
- Recruiting
- Bausch Site 002
-
Miami, Florida, United States, 33155
- Recruiting
- Bausch Site 004
-
-
Nevada
-
Henderson, Nevada, United States, 89052
- Recruiting
- Bausch Site 005
-
Las Vegas, Nevada, United States, 45242
- Recruiting
- Bausch Site 001
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject's parent(s) or legally acceptable representative has provided informed consent, using an Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved Informed Consent Form (ICF), when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated, or when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
- Males and females ages 6 to <18 years of age, inclusive, at the time of screening
- Subjects must have up-to-date immunizations according to the relevant local country guideline. Subjects must not be scheduled to be vaccinated while on study.
- Female subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test at Baseline (Day 1). A female of childbearing potential is defined as a female who is fertile, following menarche.
Exclusion Criteria:
- Received conventional systemic therapies or phototherapy for treatment of psoriasis within the last 4 weeks. Topical corticosteroids are allowed.
- Female subjects who have reached puberty and are sexually active and are unwilling to use acceptable methods of effective birth control for the duration of the study and continuing for 5 weeks after receiving the dose of study drug. Acceptable methods of effective birth control include sexual abstinence (males and females); double barrier method (male condom with spermicide in combination with one female barrier method [diaphragm, cervical cap, or contraceptive sponge)]; or hormonal birth control; or intra-uterine device.
- Female subjects who are lactating/breastfeeding or who plan to breastfeed while on study through 5 weeks after receiving the dose of study drug.
- Female subjects with a positive pregnancy test.
- Female subjects who are pregnant or planning to become pregnant while on study through 5 weeks after receiving the dose of study drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
(ages 12 to <18 years): 140 mg SC dose of brodalumab
|
140 mg SC dose
70 mg SC dose
|
Experimental: Cohort 2
(ages 6 to <12 years): 70 mg SC dose of brodalumab
|
140 mg SC dose
70 mg SC dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
maximum observed concentration (Cmax)
Time Frame: 29 Days
|
maximum (or peak) serum concentration that drug achieves in the body after drug has been administrated and prior to the administration of a second dose
|
29 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Varsha Bhatt, Bausch Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 24, 2020
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
August 2, 2017
First Submitted That Met QC Criteria
August 2, 2017
First Posted (Actual)
August 7, 2017
Study Record Updates
Last Update Posted (Actual)
August 14, 2023
Last Update Submitted That Met QC Criteria
August 9, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V01-BROA-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Brodalumab
-
AmgenWithdrawnAxial SpondyloarthritisUnited States, Canada
-
Bausch Health Americas, Inc.TerminatedPsoriasisUnited States, Germany, Poland, Switzerland, France, Canada
-
Kyowa Kirin Co., Ltd.CompletedPsoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic ErythrodermaJapan
-
Bausch Health Americas, Inc.CompletedPsoriatic ArthritisUnited States, France, Hungary, Mexico, Poland, Germany, Canada, Greece, Russian Federation, Latvia
-
MedDerm AssociatesTerminated
-
Bausch Health Americas, Inc.TerminatedPsoriatic ArthritisUnited States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
-
Bausch Health Americas, Inc.TerminatedModerate to Severe Plaque PsoriasisUnited States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
-
Bausch Health Americas, Inc.TerminatedPlaque PsoriasisUnited States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
-
Rockefeller UniversityValeant PharmaceuticalsCompletedHidradenitis SuppurativaUnited States
-
Kyowa Kirin Co., Ltd.Completed